Drug Insights

Master Rosuvastatin Search on Synapse

9 February 2024
2 min read

Rosuvastatin, a drug sold under the trade names of Ezallor and Crestor, is a small molecule that functions as an inhibitor of HMG-CoA reductase, an enzyme responsible for cholesterol synthesis in the liver. By inhibiting the production of cholesterol, rosuvastatin helps to reduce the level of cholesterol and triglycerides in the bloodstream. This drug is primarily used to treat hypercholesterolemia, hyperlipidemias, and heart failure. Although it is available in several countries, including the US, China, Japan, and the Netherlands, it has been granted Priority Review and Orphan Drug status by the FDA. Ongoing research is evaluating the effectiveness of rosuvastatin in treating other conditions, and its active indication is expanding. Nevertheless, rosuvastatin may cause side effects, and patients should be closely monitored during treatment to avoid adverse effects. Click on the image below to begin the exploration journey of Rosuvastatin through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

New Insights: Vabysmo Effectively Treats Retinal Swelling in Retinal Vein Occlusion Patients
Latest Hotspot
3 min read
New Insights: Vabysmo Effectively Treats Retinal Swelling in Retinal Vein Occlusion Patients
9 February 2024
Recent findings on Genentech's drug Vabysmo indicate persistent efficacy in reducing retinal swelling and enhancing eyesight for those with Retinal Vein Occlusion.
Read →
Unveiling Escitalopram: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Escitalopram: How to Search for it on Synapse
9 February 2024
Escitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor.
Read →
First Participant Dosed in RS Oncology's Phase 2 Trial of RSO-021 for Chest Tumor and Lung Metastases
Latest Hotspot
3 min read
First Participant Dosed in RS Oncology's Phase 2 Trial of RSO-021 for Chest Tumor and Lung Metastases
9 February 2024
RS Oncology Confirms Initial Participant Receives Dosage in Stage 2 Trial (MITOPE) Examining RSO-021 in Malignant Chest Tumor and Lung Metastases Therapy.
Read →
Expert Tips for Searching Ketamine on Synapse
Drug Insights
2 min read
Expert Tips for Searching Ketamine on Synapse
9 February 2024
Ketamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.